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ABSTRACT  
 
Background During the transition to rheumatoid arthritis (RA) many patients pass through a 
phase characterised by the presence of symptoms without clinically apparent synovitis. These 
symptoms are not well-characterised. This taskforce aimed to define the clinical 
characteristics of patients with arthralgia who are considered at risk for RA by experts based 
on their clinical experience.  
Methods The taskforce consisted of 18 rheumatologists, 2 patients, 3 health professionals and 
1 fellow. The process had three phases. In phase-1, a list of parameters considered 
characteristic for clinically suspect arthralgia (CSA) was derived; the most important 
parameters were selected by a three-phased Delphi-approach. In phase-2, the experts 
evaluated 50 existing patients on paper, classified them as CSA/no-CSA and indicated their 
level of confidence. A provisional set of parameters was derived. This was studied for 
validation in phase-3, where all rheumatologists collected patients with and without CSA 
from their outpatient clinics. 
Results The comprehensive list consisted of 55 parameters, of which 16 were considered most 
important. A multivariable model based on the data from phase-2 identified 7 relevant 
parameters: symptom duration <1-year, symptoms of MCP-joints, morning stiffness duration 
≥60 minutes, most severe symptoms in early morning, first-degree relative with RA, difficulty 
with making a fist, positive squeeze-test MCP-joints. In phase-3, the combination of these 
parameters was accurate in identifying arthralgia patients who were considered at risk of 
developing RA (AUC=0.92, 95%CI=0.87-0.96). Test characteristics for different cut-off 
points were determined. 
Conclusion A set of clinical characteristics for patients with arthralgia who are at risk of 
progression to RA was established.  
INTRODUCTION 
 
The development of rheumatoid arthritis (RA) is a multistep process. A European League 
Against Rheumatism (EULAR) study group differentiated the following phases: (1) presence 
of genetic and environmental risk factors for RA, (2) systemic autoimmunity associated with 
RA, (3) symptoms without clinical arthritis, (4) unclassified arthritis and finally (5) RA.[1] 
The symptomatic phase preceding clinical arthritis is the first opportunity to clinically 
recognise patients who are at risk for progression to RA. In contrast to the other phases that 
have been studied extensively, this phase is less well studied.  Whilst a few studies reported 
on symptoms experienced by patients in this phase and on their impact on daily life,[2–4] 
clinical characteristics that are specific for this phase have not yet been identified by a 
consensus-based approach.[1,5,6] This situation hampers the conduct of studies and clinical 
trials in this phase of the disease. It has been shown that early initiation of disease modifying 
anti-rheumatic drug (DMARD) treatment in RA is more effective in modulating the erosive 
and persisting nature of RA compared to delayed initiation of DMARD treatment.[7–9] Hence 
interventions in the initial clinical phase of the disease, which precedes the onset of clinical 
arthritis, may be more effective in reducing the risk of disease persistence and the 
development of damage.[10] However, studies to address this require the inclusion of 
homogeneous sets of patients.  
 
Clinical expertise, which includes pattern recognition, guides decisions in daily 
practice and has also been used as reference for the development of several tools or criteria in 
the field of rheumatology.[11–14] Patients with Clinically Suspect Arthralgia (CSA) have 
articular symptoms without signs of arthritis and are considered to be at increased risk for 
progression to RA.[15] Hence, the identification of the presence of CSA is based on clinical 
expertise. Recent data revealed that patients with CSA constitute only a small percentage of 
all patients with arthralgia who visit the rheumatology outpatient clinic for the first time 
(~7%), and that a proportion of patients with CSA did indeed progress to RA during follow-
up (~20%).[16] It was also suggested that clinical experience was accurate to distinguish 
patients with arthralgia at risk of RA from other arthralgia patients (OR 55). In particular, 
only a minority of patients who presented with arthralgia and subsequently developed RA 
were not recognised by the rheumatologist.[17] 
 
Although the concept of CSA is appropriate for use in clinical practice, a drawback is 
its subjectivity, which may result from differences in practice and experience. Therefore the 
phenotype of CSA needs to be defined. This taskforce aimed to identify a combination of 
clinical features that best characterise patients with arthralgia who are at risk of RA according 
to an expert multidisciplinary group of European rheumatologists, other health professionals 
and patients. This approach was similar to that which led to the definition of inflammatory 
back pain, a definition which was subsequently integrated in the ASAS classification 
criteria.[18,19] The taskforce intended to derive a set of clinical parameters to enable the 
inclusion of homogeneous sets of patients in subsequent studies. It was considered 
inappropriate to use the phrase ‘classification criteria’ for the product as, basically, 
classification concerns testing the presence or absence of a disease. CSA is not in itself a 
disease, but a combination of symptoms and signs. It was anticipated that clinical 
characteristics alone are insufficient predictive for RA, that a combination of clinical and 
other factors (e.g. autoantibodies, imaging results) are necessary to identify patients with 
imminent RA, and that the derived clinical definition can later become part of criteria for 
imminent RA. Thus in sum, the present taskforce aimed to define arthralgia at risk for RA.  
 
METHODS 
 
Expert committee 
The expert committee comprised 18 rheumatologists, one methodologist (RL, who was also 
one of the rheumatologists), two nurse specialists, one physiotherapist, two patients and one 
research fellow, originating from 15 European countries. The target populations are 
rheumatologists and health professionals working in secondary care. 
 
Three-phased process  
The process consisted of three phases and two meetings. Expert opinion was the reference. 
Per phase consensus was obtained before proceeding to the next phase.  
 
Phase-1 
Phase-1 aimed to develop a comprehensive list of clinical parameters (both symptoms at 
history taking and signs at physical examination) that were considered by the experts to be 
relevant to distinguish arthralgia that precedes RA from other types of arthralgia. A modified 
Delphi approach was used. First, all taskforce members were asked to indicate all symptoms 
and signs that they considered potentially relevant. All parameters mentioned to be relevant 
by at least two experts or by the patients (based on personal experience) were added to create 
a comprehensive list. In the next three quantitative rounds the participants selected the 
parameters they considered most relevant by weighing. After each round, the list of 
parameters was modified based on the results; parameters on which consensus was reached 
(either relevant or irrelevant) were not evaluated in the next round. The group response of the 
previous round and the modified list were presented to the group before they voted in the next 
round.  
 Phase-2 
Phase-2 aimed to develop a provisional set of clinical parameters describing CSA. The 
experts reviewed clinical data from 50 patients who had previously presented with arthralgia 
but without clinically detectable arthritis to the rheumatology outpatient clinic of the Leiden 
University Medical Centre (the Netherlands). Of these, 26 were considered to have CSA by 
the treating rheumatologist[15]; the prevalence of CSA in this patient set was thus artificial 
and much higher than in a general rheumatology outpatient clinic. The experts were blinded 
for grouping by the treating rheumatologists. Clinical data relating to the parameters selected 
in Phase-1 were presented to the experts as being present or absent in these ‘paper patients’. 
The experts were asked to classify each patient as having CSA or no-CSA and to provide the 
level of confidence with their classification on a numerical rating scale from 0 (not confident) 
to 10 (very confident).  
 
Two approaches were used to analyse the data from Phase-2. First, to gain insight into 
the degree of equivalence of the expert classifications, the frequencies of the classifications 
were plotted against the level of confidence of each classification per patient, as described 
previously.[19] Individual histograms represented all experts’ judgments on individual patient 
and were evaluated independently by three reviewers (AvdHvM, RL, HvS); each reviewer 
decided whether the experts agreed on the classification as ‘CSA’, ‘no-CSA’ or 
‘unclassifiable’. If all reviewers had the same judgment the patient was categorised 
accordingly. Otherwise, agreement between the reviewers was reached on how to categorise a 
patient. The parameters selected in phase-1 were compared for the patients in the three groups 
(CSA, no-CSA and unclassifiable). Then, to statistically identify the parameters that best 
discriminated between CSA and no-CSA, a multilevel model was used with one level being 
the expert and the other level being the patient; this analysis which was done on 900 
judgments about CSA included the data of all 50 patients, each classified by 18 
rheumatologists. This mixed effects model with crossed random effects was applied with the 
weighted CSA classification as outcome and the clinical parameters as independent variables. 
This model was used to take into account that each expert assessed the same 50 patients. 
Crossed random effects were included as the symptoms are nested in the combination of 
expert and patient and thus the residuals of the two levels are still correlated, even after taking 
the two levels of the analysis into account.[20,21] Clinical parameters with a p-value ≤0.05 in 
univariable analyses were included in multivariable analysis. The parameters with a positive 
coefficient in the multivariable analysis were combined to a provisional set of parameters 
describing CSA. These data were presented at the first meeting.  
 
Phase-3 
Phase-3 aimed to validate the provisional set of parameters in the outpatient clinics of the 
participating rheumatologists. They were asked to select newly referred patients without a 
defined time limit of symptoms and without arthritis but with arthralgia who they considered 
to have an increased risk of RA based on history taking and physical examination (patients 
with CSA) and patients who had no evident diagnosis or explanation for the arthralgia at first 
visit but were not considered at risk for RA (no-CSA). Patients who at presentation had 
evident diagnoses, such as fibromyalgia or osteoarthritis, were not included in the no-CSA 
group. In addition, the participants were encouraged to base the decision of CSA on the 
clinical presentation only and not on results of additional investigations. Due to differences in 
health care settings, some rheumatologists had access to the result(s) of laboratory or imaging 
investigation(s) at first presentation for the majority of their patients. The presence or absence 
of additional test results at the time of identification of CSA or no-CSA was recorded. The 
provisional set of parameters derived from phase-2 was tested using multivariable logistic 
regression analyses in the identified CSA and no-CSA patients. Thus again clinical expertise 
was the reference. The performance of the combination of parameters was assessed using the 
area under the receiver operating characteristic curve (AUC). Sensitivity and specificity were 
determined for different cut-off points. The data from this phase were discussed during the 
second meeting. The final set of parameters was established by voting.  
 
RESULTS 
 
Phase-1 – Identifying relevant parameters for CSA 
First, all experts identified as many parameters as possible that they considered relevant when 
evaluating whether arthralgia patients did or did not have CSA. The total list consisted of 55 
parameters (Supplementary Table S1) and included both parameters that were considered to 
increase and decrease the likelihood of CSA. By selecting and weighing in three rounds, the 
number of parameters on the list was reduced to 16 (Table 1). Consensus was reached to 
proceed with these 16 parameters to phase-2.  
 
Phase-2 – Development of provisional set of parameters describing CSA 
First, in order to get an overview of the data, each of the 50 patients were classified as having 
CSA, no-CSA or being unclassifiable based on their individual histograms which represented 
the classifications of all experts. Seventeen patients were unequivocally classified as no-CSA, 
14 as CSA and 19 patients were considered unclassifiable (examples of the histograms are 
presented in Supplementary Figure S1). Table 1 presents the frequencies of the clinical 
parameters for the groups of patients identified as no-CSA, unclassifiable and CSA.  
Then, using data from all 50 patients, a multilevel model with weighted CSA 
classification as outcome was used to select the parameters that best discriminated between 
CSA and no-CSA. Results of univariable and multivariable analyses are presented in 
Supplementary Table S2. The following 7 variables were presented during the first meeting as 
a provisional set of parameters describing CSA: joint symptoms of recent-onset (duration <1 
year), symptoms located in MCP-joints, symmetric symptoms or signs (bilateral in same joint 
region), duration of morning stiffness ≥60 minutes, most severe symptoms present in the early 
morning, difficulty with making a fist and positive squeeze-test of MCP-joints. At the 
meeting, it was suggested to remove the item symmetry from the multivariable analysis 
(because of p>0.05 in univariable analysis) and to force MTP-involvement and a positive 
family history in the analysis (as these items were judged as very relevant by many experts). 
The results are presented in Supplementary Table S3. Thereafter, consensus was reached on 
the following 7 parameters to characterise arthralgia that is clinically suspect for progression 
to RA: joint symptoms of recent-onset (duration <1 year), symptoms located in MCP-joints, 
duration of morning stiffness ≥60 minutes, most severe symptoms present in the early 
morning, presence of a first-degree relative with RA, difficulty with making a fist and positive 
squeeze-test of MCP-joints (Box 1). 
 
Phase-3 – Validation  
In total 322 patients with arthralgia were identified in the different centres (Supplementary 
Table S4), 142 patients with CSA and 180 arthralgia patients without CSA. Of them, 78 and 
61 respectively were identified based on clinical information only (i.e. without data relating to 
additional investigations); these 139 patients were used in the main analysis. When weighing 
the parameters based on the B coefficient of the logistic regression analysis after rounding the 
coefficients to whole points, the combination of 7 parameters performed well to explain the 
clinical expertise (AUC 0.93, 95%CI 0.89-0.97). When using all variables unweighted, the 
combination of 7 parameters performed equally well in identifying arthralgia patients who 
were considered to be at risk of RA by the experts (AUC 0.92, 95%CI 0.87-0.96) 
(Supplementary Table S5). The experts agreed that unweighted parameters were more 
convenient. When analysing all 322 patients, similar AUCs were obtained (Supplementary 
Table S6).  
The sensitivities and specificities belonging to the number of positive parameters are 
presented in Table 2. A sensitivity >90% was obtained in the presence of ≥3 parameters and a 
specificity >90% in the presence of ≥4 parameters. All taskforce members unanimously 
agreed that arthralgia that is suspected for progression to RA is defined by the seven 
parameters presented in Box 1 and that these parameters are to be used in patients with 
arthralgia but not clinical arthritis in whom there is not a better explanation for the arthralgia. 
 
DISCUSSION 
 
The development of RA is a multi-step process. In this project we defined the combination of 
symptoms and signs that characterise patients at risk of developing RA. In clinical practice, 
rheumatologists identify patients with CSA based on their expertise. The presence of CSA 
may trigger rheumatologists to monitor patients closely and/or to undertake specific 
laboratory testing or imaging. For daily rheumatologic practice the concept of CSA has been 
shown to be adequate to differentiate patients with arthralgia, [16,17] but it is subjective and 
this results in heterogeneity. For scientific studies homogeneous sets of patients are required. 
Therefore, we aimed to capture clinical expertise and represent it in a set of defined clinical 
parameters. The process incorporated three phases and two meetings, and the product was 
obtained by a data-driven and consensus-driven approach. Unanimous agreement was 
obtained on seven parameters reflecting the aggregated expertise of rheumatologists, health 
care professionals and patients from fifteen European countries. 
 
This taskforce was able to successfully identify and collate a homogenous and 
measurable set of clinical parameters of CSA based on clinical expertise of rheumatologic 
experts for use in future studies. Further longitudinal studies are required to assess if this 
definition reduces the number of arthralgia patients that need additional testing, and to 
determine the predictive accuracy of these clinical parameters for the development of RA, 
both when used alone and in combination with the results of additional investigations. Thus, 
the result of this taskforce should serve as the basis for the next step, which is the initiation of 
longitudinal data-driven projects, which ultimately results in the development of criteria for 
imminent RA. Most likely such criteria will include both clinical and investigation based 
parameters (such as laboratory and imaging results).  
 
Because a clinical definition alone is unlikely to be sufficiently accurate to identify 
RA patients in a symptomatic pre-arthritis phase, and because CSA is not a disease but the 
description of a phenotype, it was decided that the product of this taskforce should not be 
referred to as ‘classification criteria’ but as a ‘definition’. Furthermore, while the physicians 
in the taskforce argued that the word ‘patient’ may have an unwarranted connotation, the 
patient representatives in the task force justified the use of the term ‘patient’ by pointing to 
the fact that these individuals had presented with pain and other symptoms and had been 
referred to secondary care.  
 
The parameters characterising arthralgia at risk of RA may serve as the basis for 
observational studies and intervention trials performed in the symptomatic pre-arthritis phase. 
Depending on the study a more sensitive or more specific definition may be preferred. A high 
sensitivity may be preferred if the clinical criteria are used as first inclusion criterion, as in 
this situation the number of CSA patients that are missed by the criteria should be low. 
Subsequently, additional tests can be applied to ensure sufficient specificity. If in contrast, 
patients are mainly selected based on clinical characteristics, a higher specificity may be 
preferred to prevent false-positives. Given this, the taskforce deliberately avoided a single cut-
off point to define arthralgia at risk of RA, but provided the test characteristics of a spectrum 
of cut-off points. A high sensitivity (>90%) is obtained if ≥3 out of the 7 parameters are 
present; a high specificity (>90%) requires the presence of ≥4 of the 7 parameters.  
 
The clinical variables were considered to distinguish arthralgia patients who are at risk 
of RA from patients with other types of (not specified) arthralgia. Patients that at first 
presentation clearly had other diagnoses, such as fibromyalgia or osteoarthritis, were not 
included in the control groups of phases 2 and 3. This is in line with clinical practice, as there 
is no diagnostic dilemma in the patients with evident diagnoses. Similar to the 2010 
ACR/EULAR classification criteria for RA that should not be applied to arthritis patients with 
diagnoses other than RA [14], the present set of parameters is reserved for patients with 
arthralgia with no definitive diagnosis but a clinical suspicion of RA. 
 
The definition was derived for use in secondary care. Because of this target 
population, the taskforce was composed largely of rheumatologists and their expertise was 
used as a reference. General practitioners were not involved. The taskforce discussed whether 
our present product may be useful as a referral tool for general practitioners, as has been done 
by others [22]. Whilst the taskforce was of the opinion that the present set of parameters 
might also be valuable to identify patients with arthralgia at risk of RA in primary care, it was 
agreed that the applicability of the present definition in the primary care setting would need to 
be assessed through future research in primary care.  
 
It was acknowledged that there may be some redundancy in the seven parameters 
expressing risk for RA. Further prospective studies will be required to elucidate if one of the 
parameters can be omitted without losing discriminative ability.  
 
A limitation of our approach is that the experts who developed the list of relevant 
parameters in Phase-1 and scored the patients in Phase-2 also identified patients for the 
validation phase. It is possible that the discussions that were held and the data from the first 
two phases influenced their clinical expertise while selecting patients with CSA and arthralgia 
patients without CSA. However many experts also involved other colleagues to select patients 
with CSA from their clinics and these colleagues were not involved in the first two phases of 
the project.  
 
Differences in health care settings affect the ability to identify patients in a 
symptomatic phase prior to presenting with clinically apparent arthritis. E.g., between centres 
and countries there are differences in the possibilities for early access. Some of the differences 
between health care settings were incorporated by inviting experts from different centres and 
different countries and by using a consensus-based approach. There were also differences in 
the extent to which additional investigations were performed prior to the first clinical 
evaluation in speciality care. As the aim of the taskforce was to provide a clinical definition, 
and as knowledge of the results of additional investigations may influence the selection of 
patients in phase 3, patients in whom knowledge of additional investigations were known at 
first presentation were initially excluded from analyses. This ensured that patients were 
exclusively identified on the clinical presentation. However, a sub-analysis including also the 
other patients did not give different results, revealing robustness of the data.  
 
The taskforce had discussed if the individual parameters needed to be defined. 
Consensus was derived that this project was not aiming at what definition of a specific 
domain was best, but rather what domains contribute most to the ‘phenotype’ of CSA, given 
all the restrictions.  
 
In conclusion, a set of clinical characteristics describing arthralgia at risk of RA was 
established. The combination of these parameters accurately reflected expert opinion about 
CSA. Test characteristics were determined for different cut-off points. For a sensitive 
definition, arthralgia at risk of RA can be defined by the presence of ≥3 parameters and the 
presence of ≥4 parameters yielded a high specificity. Longitudinal studies are required to 
determine the predictive accuracy of these clinical parameters alone and when combined with 
the results of additional investigations, such as laboratory testing or imaging. 
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Table 1. Parameters that were selected in phase-1, and frequencies of these parameters 
in the patients that in phase-2 were categorised as CSA, no-CSA or were considered 
unclassifiable 
 
 
 
No-CSA 
(n=17) 
Unclassifiable 
(n=19) 
CSA 
(n=14) 
History taking    
  Joint symptoms of recent-onset (duration <1 year)  41% 74% 92% 
  4-10 joints with symptoms 47% 57% 21% 
  Symptoms in MCP-joints 35% 63% 93% 
  Symptoms in MTP-joints 35% 53% 57% 
  Symptoms in several small joint regions (MCP,  
  wrists, PIP, MTP-joints) 
35% 68% 93% 
  Symmetric symptoms or signs (bilateral in same  
  joint region) 
77% 58% 100% 
  Duration of morning stiffness ≥60 minutes 6% 37% 71% 
  Most severe symptoms in the early morning 27% 69% 90% 
  Improvement of symptoms during the day 15% 36% 90% 
  Increasing number of joints with symptoms over  
  time 
70% 71% 90% 
  Patient-experience of swelling of small hand  
  joints 
31% 47% 77% 
  Presence of a first-degree relative with RA 7% 33% 36% 
Physical examination    
  Difficulty with making a fist 8% 31% 43% 
  Local tenderness involved joints at physical  
  examination 
63% 84% 86% 
  Positive squeeze-test of  MCP-joints 14% 26% 69% 
  Positive squeeze-test of  MTP-joints 22% 21% 39% 
 
Data on symptoms of recent-onset was missing in 1 patient, on most severe symptoms in early 
morning in 6 patients, on improvement of symptoms during the day in 8 patients, on 
increasing number of joints with symptoms over time in 11 patients, on patient-experience of 
swelling in 2 patients, on difficulty with making a fist, presence of a first-degree relative with 
RA, local tenderness of joints, squeeze-test of MCP- and MTP-joints in 4 patients. 
  
Table 2. Sensitivities and specificities for the presence of arthralgia at risk of RA with 
the clinical expertise on CSA as reference  
 
Number of 
parameters present 
Sensitivity Specificity 
≥ 1 100.0% 14.1% 
≥ 2 98.4% 53.8% 
≥ 3 90.2% 74.4% 
≥ 4 70.5% 93.6% 
≥ 5 32.8% 100.0% 
≥ 6 16.4% 100.0% 
≥ 7 1.6% 100.0% 
Box 1. EULAR defined characteristics describing arthralgia at risk for RA  
 
These parameters are to be used in patients with arthralgia without clinical arthritis and  
without other diagnosis or other explanation for the arthralgia. 
 
History taking: 
• Joint symptoms of recent-onset (duration <1 year) 
• Symptoms located in MCP-joints 
• Duration of morning stiffness ≥60 minutes 
• Most severe symptoms present in the early morning 
• Presence of a first-degree relative with RA 
Physical examination: 
• Difficulty with making a fist 
• Positive squeeze-test of  MCP-joints 
 
 
 
 
